9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Viking Therapeutics Enters Underwriting Agreement for Equity Offering
Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
Financial Results, Press Release
Shareholder votes
Reports First Quarter 2026 Financial Results and Provides Corporate Update
Annual Report to Security Holders
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 305(b)(2)
Free Writing Prospectus
Definitive Revised Proxy Statement
Submission Upload
Correspondence